These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 24120259

  • 1. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
    Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D, Pongskul C, Avihingsanon Y, Tassaneeyakul W.
    Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y.
    Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E, Şahin G, Kaltuş Z, Çolak E.
    Clin Lab; 2019 Nov 01; 65(11):. PubMed ID: 31710427
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, Inui K.
    Pharmacogenetics; 2004 Jul 01; 14(7):471-8. PubMed ID: 15226679
    [Abstract] [Full Text] [Related]

  • 9. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
    Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y.
    Clin Pharmacol Ther; 2007 Dec 01; 82(6):711-25. PubMed ID: 17495880
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
    Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, De Meyer M, Malaise J, Eddour DC, Lison D, Squifflet JP, Haufroid V.
    Transplantation; 2005 Oct 15; 80(7):977-84. PubMed ID: 16249748
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G, Jing L, Deng-Qing L, Hong-Shan Z, Shai-Hong Z, Xin-Min N.
    Transplant Proc; 2010 Nov 15; 42(9):3455-8. PubMed ID: 21094796
    [Abstract] [Full Text] [Related]

  • 14. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F.
    Clin Pharmacokinet; 2013 Sep 15; 52(9):751-62. PubMed ID: 23633119
    [Abstract] [Full Text] [Related]

  • 15. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD.
    Transplant Proc; 2012 Jan 15; 44(1):109-14. PubMed ID: 22310591
    [Abstract] [Full Text] [Related]

  • 16. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
    Díaz-Molina B, Tavira B, Lambert JL, Bernardo MJ, Alvarez V, Coto E.
    Transplant Proc; 2012 Nov 15; 44(9):2635-8. PubMed ID: 23146479
    [Abstract] [Full Text] [Related]

  • 17. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T.
    Transplantation; 2004 Oct 27; 78(8):1182-7. PubMed ID: 15502717
    [Abstract] [Full Text] [Related]

  • 18. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O.
    Fundam Clin Pharmacol; 2007 Aug 27; 21(4):427-35. PubMed ID: 17635182
    [Abstract] [Full Text] [Related]

  • 19. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.
    Zhang X, Wang Z, Fan J, Liu G, Peng Z.
    Eur J Clin Pharmacol; 2011 Aug 27; 67(8):803-13. PubMed ID: 21359536
    [Abstract] [Full Text] [Related]

  • 20. Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms.
    Soda M, Fujitani M, Michiuchi R, Shibayama A, Kanamori K, Yoshikuni S, Ohno Y, Tsuchiya T, Suzuki A, Horie K, Deguchi T, Itoh Y, Kitaichi K.
    Transplant Proc; 2017 Aug 27; 49(6):1492-1498. PubMed ID: 28736028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.